Finch Therapeutics Group, Inc. (FNCH)

NASDAQ: FNCH · IEX Real-Time Price · USD
0.950
-0.010 (-1.03%)
Dec 5, 2022 4:00 PM EST - Market closed
-1.03%
Market Cap 45.99M
Revenue (ttm) 1.66M
Net Income (ttm) -106.69M
Shares Out 47.73M
EPS (ttm) -1.45
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 23,395
Open 1
Previous Close 0.96
Day's Range 0.9 - 1
52-Week Range 0.83 - 14.87
Beta n/a
Analysts Buy
Price Target 13.52 (+1,322.9%)
Earnings Date Nov 9, 2022

About FNCH

Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States. The company's lead candidate is CP101, an orally administered microbiome capsule that is in Phase 3 clinical trial for the treatment of patients with recurrent Clostridioides difficile infection, as well as for the treatment of chronic hepatitis B virus. It is also developing FIN-211, an orally administered enriched consortia product candidate for use in the treatment of autism sp... [Read more]

Industry Biotechnology
IPO Date Mar 19, 2021
Employees 189
Stock Exchange NASDAQ
Ticker Symbol FNCH
Full Company Profile

Financial Performance

In 2021, FNCH's revenue was $18.53 million, an increase of 140.08% compared to the previous year's $7.72 million. Losses were -$58.16 million, 47.8% more than in 2020.

Financial Statements

Analyst Forecast

According to 9 analysts, the average rating for FNCH stock is "Buy." The 12-month stock price forecast is 13.52, which is an increase of 1,322.86% from the latest price.

Price Target
$13.52
(1,322.86% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Finch Therapeutics Group, Inc. (FNCH) Reports Q3 Loss, Misses Revenue Estimates

Finch Therapeutics Group, Inc. (FNCH) delivered earnings and revenue surprises of -12.50% and 90.80%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for...

3 weeks ago - Zacks Investment Research

Finch Therapeutics Provides Corporate Updates and Reports Third Quarter 2022 Financial Results

SOMERVILLE, Mass., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics”) (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveraging its Huma...

3 weeks ago - GlobeNewsWire

Finch Therapeutics to Present at the Jefferies London Healthcare Conference and Evercore ISI HealthCONx Conference

SOMERVILLE, Mass., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics”) (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveraging its Huma...

3 weeks ago - GlobeNewsWire

Finch Therapeutics Group, Inc. (FNCH) Upgraded to Buy: Here's Why

Finch Therapeutics Group, Inc. (FNCH) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

3 months ago - Zacks Investment Research

Finch Therapeutics Regains Full Rights to FIN-524 and FIN-525 Targeted Microbiome Product Candidates in Development f...

SOMERVILLE, Mass., Aug. 25, 2022 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics”) (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveraging its Huma...

3 months ago - GlobeNewsWire

Finch Therapeutics to Participate in Upcoming June Investor Conferences

SOMERVILLE, Mass., June 02, 2022 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics”) (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveraging its Huma...

6 months ago - GlobeNewsWire

Finch Therapeutics Provides Corporate Update and Reports First Quarter 2022 Financial Results

SOMERVILLE, Mass., May 16, 2022 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics”) (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveraging its Human...

6 months ago - GlobeNewsWire

Finch Therapeutics to Host Corporate Update Conference Call and Webcast on May 16, 2022

SOMERVILLE, Mass., May 09, 2022 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics”) (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveraging its Human...

6 months ago - GlobeNewsWire

Why Finch Therapeutics Stock Is Skyrocketing Today

The FDA, at long last, has lifted a clinical hold on Finch's C. diff program.

7 months ago - The Motley Fool

Why Is Finch Therapeutics (FNCH) Stock Up 30% Today?

Finch Therapeutics (FNCH) stock is rising higher on Friday following news that the FDA has released its clinical hold on CP101. The post Why Is Finch Therapeutics (FNCH) Stock Up 30% Today?

7 months ago - InvestorPlace

Finch Therapeutics Announces Removal of FDA Clinical Hold on CP101 IND

SOMERVILLE, Mass., April 28, 2022 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics”) (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveraging its Hum...

7 months ago - GlobeNewsWire

Finch Therapeutics Announces Workforce Restructuring to Focus Resources on Key Development Programs

SOMERVILLE, Mass., April 19, 2022 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics”) (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveraging its Hum...

7 months ago - GlobeNewsWire

Finch Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Updates

SOMERVILLE, Mass., March 31, 2022 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics”) (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveraging its Hum...

8 months ago - GlobeNewsWire

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Finch Therapeutics Group, Inc. - ...

NEW YORK , March 26, 2022 /PRNewswire/ --Pomerantz LLP is investigating claims on behalf of investors of Finch Therapeutics Group, Inc. ("Finch" or the "Company") (NASDAQ: FNCH).  Such investors are adv...

8 months ago - PRNewsWire

See Why Did Finch Therapeutics Halt Enrolment In Late-Stage C. Difficile Infection Trial

The FDA has issued a clinical hold letter to Finch Therapeutics Group Inc's (NASDAQ: FNCH) PRISM4 Phase 3 trial of CP101 in recurrent C. difficile infection (CDI).

9 months ago - Benzinga

Finch Therapeutics Provides an Update on its Phase 3 Trial of CP101 in Recurrent C. difficile Infection

SOMERVILLE, Mass., March 01, 2022 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics” or “Company”) (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company lever...

9 months ago - GlobeNewsWire

Finch Therapeutics to Participate in the Chardan Metagenomics and Microbiome Medicines Summit

SOMERVILLE, Mass., Feb. 23, 2022 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics”) (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveraging its Huma...

9 months ago - GlobeNewsWire

Finch Therapeutics Announces Additions to Senior Leadership Team

SOMERVILLE, Mass., Feb. 10, 2022 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics”) (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveraging its Huma...

9 months ago - GlobeNewsWire

Finch Therapeutics Further Strengthens Patent Portfolio with Two New U.S. Patents Granted for FIN-211, an Investigati...

SOMERVILLE, Mass., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics”) (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveraging its Huma...

10 months ago - GlobeNewsWire

Finch Therapeutics Appoints Joseph Vittiglio, JD, as Chief Business and Legal Officer

SOMERVILLE, Mass., Dec. 20, 2021 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics”) (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveraging its Huma...

11 months ago - GlobeNewsWire

Finch Therapeutics' C. Difficile Infection Candidate Meets Primary Goal In Mid-Stage Study

Finch Therapeutics Group Inc (NASDAQ: FNCH) announced positive topline results from PRISM-EXT, an open-label extension of the PRISM3 Phase 2 trial evaluating CP101 to prevent recurrent C. difficile infe...

1 year ago - Benzinga

Finch Therapeutics Reports Third Quarter 2021 Financial Results and Provides Business Updates

SOMERVILLE, Mass., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics”) (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveraging its Huma...

1 year ago - GlobeNewsWire

Finch Therapeutics Announces Transition of Chief Medical Officer

SOMERVILLE, Mass., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics”) (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveraging its Huma...

1 year ago - GlobeNewsWire

Finch Therapeutics Announces Positive Topline Results from PRISM-EXT Phase 2 Trial of CP101 for Prevention of Recurre...

SOMERVILLE, Mass., Nov. 09, 2021 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics”) (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveraging its Huma...

1 year ago - GlobeNewsWire

Finch Therapeutics Presents Positive Data from PRISM3 Clinical Trial of CP101 for Recurrent C. difficile at American ...

SOMERVILLE, Mass., Oct. 25, 2021 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics”) (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveraging its Huma...

1 year ago - GlobeNewsWire